German Court Court Affirms Injured Covid-19 Vaccinated Right To Access Manufacturer Data, Forcing Disclosure

TRUTH11.COM
21 Apr 2026 4 min

Share

BioNTech Ordered To Hand Over 32 Internal Safety, Toxicity, and Manufacturing Records on 'Comirnaty' COVID-19 mRNA Vaccine

Subscribe

> The ruling directly addresses a core imbalance that has defined vaccine injury litigation: injured **individuals have been expected to prove causation while being denied access to the very data needed to do so.**

TheLibertyBeacon.com

Jon Fleetwood | jonfleetwood.substack.com

In a major procedural victory for vaccine-injured plaintiffs, a German court has ordered BioNTech to turn over internal data on its Comirnaty mRNA COVID-19 vaccine—affirming that individuals claiming harm have the right to access the manufacturer's own records to challenge its safety claims and pursue damages.

The Regional Court of Aurich (Landgericht Aurich), in case 5 O 1106/24, issued a **certified partial judgment** (“Teilurteil”) ordering BioNTech Manufacturing GmbH to provide **detailed information on the vaccine’s effects, side effects, and underlying biological and manufacturing characteristics.**

The court’s order states, translated and paraphrased for readability:

The defendant is ordered … to provide information … on the effects and side effects known to it … as well as on other findings that may be relevant for the assessment of the justifiability of harmful effects …

The ruling directly addresses a core imbalance that has defined vaccine injury litigation: injured **individuals have been expected to prove causation while being denied access to the very data needed to do so.**

This decision breaks that barrier.

Independent journalist Bastian Barucker first reported on the ruling.

Beglaubigte Abschrift

Landgericht
Aurich

Im Namen des Volkes

Teilurteil

5 O 1106/24

In dem Rechtsstreit

[redacted]

- Klägerin -

Prozessbevollmächtigte:
Rogert & Ulbrich Rechtsanwälte in Partnerschaft mbB, Niermannsweg 11 - 15, 40699 Erkrath
Geschäftszeichen: 1035/24

gegen

BioNTech Manufacturing GmbH, An der Goldgrube 12, 55131 Mainz

- Beklagte -

Prozessbevollmächtigte:
Rechtsanwälte und Rechtsanwältinnen CliffordChance Partnerschaft mit beschr. Berufshaftung, Junghofstraße 14, 60311 Frankfurt am Main
Geschäftszeichen: 40-41101612

w e g e n Schmerzensgeld, Schadensersatz und Auskunft nach Corona-Impfung

Court Order Forces Disclosure Across Manufacturing, Biology, and Safety

The certified judgment ("Beglaubigte Abschrift")—posted by **Tobias Ulbrich** (@AnwaltUlbrich), the plaintiff's lead lawyer from Rogert & Ulbrich—shows the court is not ordering narrow or limited disclosure.

It is compelling BioNTech to provide specific, technical categories of internal data, including:

Toxicity and immunological effects of **lipid nanoparticles** (ALC-0159, ALC-0315)

Pharmaceutical purity and variability of key components

Manufacturing processes, suppliers, and batch-level differences

Residual DNA contamination and sequencing data ("Process 2")

Spike protein design, function, and biological behavior (including ACE2 interaction and cleavage mechanisms)

Whether **spike protein** remains membrane-bound or becomes freely circulating in the body

Biodistribution and **potential exposure of organs and tissues**

Pharmacovigilance data on recorded injuries matching the plaintiff's conditions

Genotoxicity findings in humans

Reproductive and fertility-related effects

Sex-based risk differences, including higher risk signals in women

Cancer-related mechanisms, including P53 interaction and oncomiR findings

Internal evaluations tied to risk-benefit assessments

Batch-specific quality control and contamination measurements

Quantification of spike protein production in the body

These categories align with a broader disclosure request submitted by the plaintiff —commonly circulated as a "32-point" data list—now substantiated by the court's order itself.

GERMAN LANDGERICHT AURICH ORDERS BIONTECH TO DISCLOSE 32 KEY DATA POINTS ON COMIRNATY MRNA VACCINE

PARTIAL JUDGMENT (AZ. 5O 1106/24) - FULL TRANSPARENCY REQUIRED FOR ONGOING VACCINE INJURY LAWSUITS.

1. **Exact lipid composition**: What is the precise mixing ratio of the four lipids used?
2. **Integrity of the mRNA**: What portion of the mRNA was intact and what portion fragmented?
3. **DNA contamination**: Information on residues of plasmid DNA from the manufacturing process.
4. **Identity of all excipients**: A complete list of all added substances and their purity.
5. **Batch variability**: Why do the damage reports differ so drastically between different production numbers?
6. **Stability of the mRNA**: Documentation on degradation products and their potential toxicity.
7. **Organ biodistribution**: Exactly where do the particles (LNPs) accumulate in the human body?
8. **Duration of spike production**: Over what period do the cells produce the protein after injection?
9. **Quantification of the spike protein**: How high is the concentration of the produced protein in the bloodstream?
10. **Cell specificity**: Into which cell types does the mRNA preferentially enter?
11. **Barrier penetration**: Data on passage of the blood-brain barrier and the placenta.
12. **Comprehensive suspicion reports**: All reports of side effects available to the manufacturer worldwide.
13. **Severity analysis**: Details on the intensity and duration of the reported health damages.
14. **Cardiovascular risks**: Specific data on myocarditis, heart attacks, and strokes.
15. **Neurological disorders**: Documentation on paralysis, nerve damage, and autoimmune processes.
16. **Death case documentation**: All reports in temporal proximity to the administration of the vaccine.
17. **Long-term toxicity**: Safety data from observational studies over a period of several years.
18. **Individual patient data**: Anonymized individual data of the study participants from the original approval phases.
19. **Exclusion analyses**: Why were certain participants removed from the final study evaluation?
20. **Placebo unblinding**: Why was the control group vaccinated prematurely, complicating long-term comparisons?
21. **Infection transmission**: Was there scientific proof of protection for third parties available at market launch?
22. **Interaction studies**: Findings on interactions with other medications or vaccines.
23. **Warning history**: From what point in time did the manufacturer have information on specific risks?
24. **Authority correspondence**: Complete disclosure of communication with the PEI and the EMA.
25. **Safety reports (PSURs)**: All regular status reports submitted to the supervisory authorities.
26. **Liability provisions**: According to the contracts, who bears the financial responsibility for damages incurred?
27. **Reverse transcription**: Studies on the possible integration of mRNA sequences into human DNA.
28. **Antibody-dependent enhancement (ADE)**: Risk assessment of a possible worsening of infections.
29. **Reproductive toxicity**: Data on the impact on fertility and the female cycle.
30. **Oncogenic potential**: Studies or reports on the acceleration of cancer diseases or reactivation of dormant tumours.
31. **Immunosuppression**: Data on the temporary weakening of the body's own immune defence after vaccination.
32. **Quality control**: Who carried out the detailed release testing of the individual batches and what defects were found?. '

Plaintiff Presented Evidence of Severe Post-Vaccination Injury

The case involves a woman who received two doses of Comirnaty in 2021 and subsequently developed multiple conditions, including:

Autoimmune disease

Circulatory disorders

Vascular occlusion

Cardiac arrhythmias

Hyperinflammation syndrome

Neurological dysfunction

Menstrual disruption

Court records indicate **no clear pre-existing conditions** prior to vaccination.

The court found these claims sufficient to trigger the manufacturer's obligation to disclose all relevant internal findings.

Court: Manufacturer Must Provide What It Knows

The ruling makes clear that disclosure is not limited to publicly available summaries or pre-selected data.

It extends to:

all effects, side effects, and findings known to the manufacturer relevant to evaluating potential harm

The court further emphasized that regulatory approval does not eliminate the need for **independent evidentiary review**—especially in cases where plaintiffs allege injury.

Builds on National Precedent Expanding Access to Data

The decision follows a March 2026 ruling by Germany's Federal Court of Justice (BGH), which affirmed that plaintiffs have a right to comprehensive access to manufacturer-held data under §84a of the Medicines Act.

Judges in Aurich applied that precedent directly, reinforcing that without access to this data, injured individuals cannot meaningfully challenge a manufacturer's claims or present expert evidence.

Plaintiff's Legal Team Signals Broader Impact

Attorney Tobias Ulbrich, representing the plaintiff, described the ruling as the **beginning of a broader shift in litigation strategy,** arguing that failure to provide required information could itself carry legal consequences for manufacturers.

He compared the situation to past German litigation against **Volkswagen**, where courts ruled against the company after it **failed to fully disclose technical details** tied to alleged wrongdoing.

Not a Final Liability Ruling—But a Forced Opening of the Data

The court did **not** determine that the vaccine caused the plaintiff's injuries.

It issued a **partial judgment requiring disclosure.**

But the immediate effect is that **BioNTech must now provide internal data on how the vaccine was made, how it behaves in the body, and what adverse effects were known to the company.**

Bottom Line

A certified German court ruling has ordered BioNTech to disclose internal data on its mRNA vaccine—covering manufacturing, biological activity, and recorded adverse effects—in an **active injury case.**

The decision affirms that individuals claiming harm are entitled to access the manufacturer's own data to test those claims in court.

The case is not resolved.

But the data is no longer out of reach.

Source: https://jonfleetwood.substack.com/p/german-court-orders-biontech-to-hand?publication_id=520511&post_id=194306000&isFreemail=true&r=b8lla&triedRedirect=true

Original Article: https://www.thelibertybeacon.com/german-court-orders-biontech-to-hand-over-32-internal-safety-toxicity-and-manufacturing-records/

COMMENTS (0)

Subscribe to Truth11.com

Receive Articles By Email • Support Independent Media

Subscribe now

Support Truth11.com | • Make A Donation

• Become A Monthly Subscriber

TRUTH11.COM | Armed With The Truth • United We Stand

© Truth11.com 2026